Terns Pharma is due to release data from an early-stage trial of an obesity treatment in pill form in the second half. Positive data would send the stock higher.
This small-cap stock is expected to take off — if its weight-loss pill trial succeeds
Read Next
- Biden confronts Gaza, 2024 election weak spots in Morehouse speech
- Stocks may rise into the summer. These 3 risks could derail the rally.
- The biggest earnings heavy hitter reports this week, and so do Target and other retailers
- Currency Speculators raise Euro & US Dollar bets into positive levels :: InvestMacro
- The year of AI PCs
- Exclusive: XTX Markets sees 19% decline in 2023 UK Revenues to £2.0 billion
- Speculator bets led higher by Corn & Wheat :: InvestMacro
